BIOANMSHealthcare·Drug Manufacturers - Specialty & Generic#33 in industry

BioAge Labs, Inc.

Reports in 8d· 2026-05-05

-7.7% · 90d

$18.10

+1.05 (+6.16%)

News

(1)

April 2026

Apr 21, 20266 days agoDEF 14AHealthcare

BioAge Labs Proxy details 2026 votes on board directors and KPMG audit firm

BIOABioAge Labs, Inc.

# 📜 What This Document Is 🗳️ This is a Proxy Statement (DEF 14A), which is a required legal document filed by BioAge Labs, Inc. 📄. Think of it as the official instruction manual for the company's annual meeting. It doesn't report on the company's daily sales, but rather details the formal busines

Read summaryView on SEC EDGAR

Key Data

Market Cap$803.6M

Open$17.13

Prev Close$17.05

Day Range$17.13 – $18.85

52W Range$3.67 – $24.00

Volume267,714

P/E (TTM)—

EPS$-2.24

Dividend Yield—

Beta—

Price Target$53.33(+194.7%)

Next Earnings2026-05-05(8d)

Analyst Ratings

Strong Buy7 analysts

Buy 5Hold 2Sell 0

About

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Healthcare · Drug Manufacturers - Specialty & Generic

60 employees

bioagelabs.com